Jazz Pharma to Acquire ARS Pharma for $1B
Ticker: SPRY · Form: 8-K · Filed: Aug 28, 2025 · CIK: 1671858
| Field | Detail |
|---|---|
| Company | Ars Pharmaceuticals, Inc. (SPRY) |
| Form Type | 8-K |
| Filed Date | Aug 28, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, cash-deal
TL;DR
Jazz Pharma buying ARS for $1B cash, $21.50/share. Deal expected Q4 2025.
AI Summary
ARS Pharmaceuticals, Inc. announced on August 13, 2025, that it has entered into a definitive agreement to be acquired by Jazz Pharmaceuticals plc. The transaction is valued at approximately $1.0 billion, with Jazz Pharmaceuticals acquiring all outstanding shares of ARS common stock for $21.50 per share in cash. The acquisition is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by Jazz Pharmaceuticals significantly expands its respiratory portfolio and provides a substantial cash payout for ARS Pharmaceuticals shareholders.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until completion.
Key Numbers
- $1.0B — Acquisition Value (Total cash consideration for ARS Pharmaceuticals)
- $21.50 — Per Share Price (Cash to be paid to ARS shareholders)
Key Players & Entities
- ARS Pharmaceuticals, Inc. (company) — Company being acquired
- Jazz Pharmaceuticals plc (company) — Acquiring company
- $1.0 billion (dollar_amount) — Total acquisition value
- $21.50 (dollar_amount) — Per share acquisition price
- August 13, 2025 (date) — Date of definitive agreement
- fourth quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition?
The acquisition is valued at approximately $1.0 billion.
What is the per-share price for ARS Pharmaceuticals' common stock?
Jazz Pharmaceuticals will acquire all outstanding shares of ARS common stock for $21.50 per share in cash.
Who is acquiring ARS Pharmaceuticals?
Jazz Pharmaceuticals plc is acquiring ARS Pharmaceuticals, Inc.
When is the acquisition expected to close?
The transaction is expected to close in the fourth quarter of 2025.
What is the date of the definitive agreement?
The definitive agreement was entered into on August 13, 2025.
Filing Stats: 791 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2025-08-27 21:45:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SPRY The Nasdaq
Filing Documents
- d88536d8k.htm (8-K) — 27KB
- 0001193125-25-190202.txt ( ) — 142KB
- spry-20250813.xsd (EX-101.SCH) — 3KB
- spry-20250813_lab.xml (EX-101.LAB) — 18KB
- spry-20250813_pre.xml (EX-101.PRE) — 11KB
- d88536d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARS PHARMACEUTICALS, INC. Date: August 27, 2025 By: /s/ Richard Lowenthal, M.S., MSEL Richard Lowenthal, M.S., MSEL President and Chief Executive Officer (Principal Executive Officer) 3